-1280x720-800x450.jpg)
- Pregnancy technology company HeraMED (HMD) enters a trading halt as the company prepares to undertake a capital raise
- Trading of HMD shares will be paused until Wednesday, August 24, or until the company releases further details
- HMD’s HeraCARE remote pregnancy monitoring technology has been in focus recently, after the company executed a partnership with e-Lōvu Health last month to supply the product the expectant mothers in the US
- At the end of the last quarter, the company had US$1.86 million (A$2.69 million) in available funding, which was estimated to last just over two quarters
- Shares in HMD last traded at 15 cents each on August 19
Pregnancy technology company HeraMED (HMD) has entered a trading halt as the company prepares to undertake a capital raise.
Trading of HMD shares will be paused until Wednesday, August 24, or until the company releases further details.
It is not yet known how much it is looking to raise or where the funds will be directed.
The company has a number of products specialising in digitally monitoring pregnancies.
Its HeraCARE remote pregnancy monitoring technology has been in focus recently, after the company executed a partnership with e-Lōvu Health last month to supply the product the expectant mothers in the US.
At the end of the last quarter, the company had US$1.86 million (A$2.69 million) in available funding, which was estimated to last just over two quarters.
Shares in HMD last traded at 15 cents each on August 19.